Barclays maintains an 'Equalweight' on Amylin Pharmaceuticals (NASDAQ: AMLN), PT $12.

Barclays analyst says, "We are maintaining our rating on ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE